Active pharmaceutical ingredients supplier Novadoz Pharmaceuticals reported on Thursday the receipt of the US FDA's approval for its generic versions of Oseltamivir Phosphate Capsules and Dofetilide Capsules.
According to the company, Dofetilide in 125mcg, 250mcg and 500mcg capsules is AB rated to Pfizer's brand Tykosin. Oseltamivir Phosphate in 30mg, 40mg and 75mg capsules is AB rated to Genentech Pharmaceuticals' Tamiflu.
Dofetilide is an antiarrhythmic drug used sustain a normal heart beat in patients with certain heart rhythm disorders of the atrium. It is used to treat atrial fibrillation, or atrial flutter. Combined brand and generic sales for the product exceed USD63.4m.
Oseltamivir Phosphate is used to treat symptoms caused by the flu virus (influenza) including blocked nasal passages, fever/chills, aches and fatigue. Combined sales for brand and generics amount to over USD188m.
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
International Isotopes Inc to change name to Radnostix Inc
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz
Padagis invests USD36m to expand manufacturing in Minneapolis
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream